Drugmakers seize on biomarkers to test the FDA's rare disease shift
For the first time, the FDA will consider whether to approve a trio of drugs for tiny patient populations based on trials that are using …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
